Three-Year and Five-Year Outcomes of a Phase II Study of Perioperative CapeOxTherapy for Advanced Gastric Cancer with Extensive Lymph Node Metastasis (OGSG1701)

A Multicenter Phase II Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Final outcomes of the phase II OGSG1902 trial

Conversion Surgery for Stage IV Gastric Cancer: Real-World Insights with a Focus on Elderly Patients (OGSG2301)

Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)

ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for patients with gastrointestinal cancer and iron deficiency anemia undergoing chemotherapy

Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial

Identification of Prognostic Factors and Construction of Prognostic Index for Later-line Treatment in Advanced Gastric Cancer: Sub-analysis from the Phase III RINDBeRG Trial

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)